Mira Jung
Founder at SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Net worth: 568 907 $ as of 2024-05-30
Profile
Mira Jung is the founder of Shuttle Pharmaceuticals, Inc. (founded in 2012) and Shuttle Pharmaceuticals Holdings, Inc. (founded in 2012) where she holds the title of Scientific Director and Chief Scientific Officer-Biology respectively.
Dr. Jung also worked as a Professor at Georgetown University School of Medicine.
She obtained her graduate and doctorate degrees from the University of Kansas.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-20 | 1,071,388 ( 6.38% ) | 568 907 $ | 2024-05-30 |
Mira Jung active positions
| Companies | Position | Start |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Founder | 2012-12-17 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Founder | 2012-11-30 |
Former positions of Mira Jung
| Companies | Position | End |
|---|---|---|
| Georgetown University School of Medicine | Corporate Officer/Principal | - |
Training of Mira Jung
| University of Kansas | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Mira Jung
